Menu
Search
|

Menu

Close
X

Alder Biopharmaceuticals Inc ALDR.OQ (NASDAQ Stock Exchange Global Market)

10.11 USD
-- (--)
As of Jul 18
Previous Close 10.11
Open --
Volume --
3m Avg Volume 295,142
Today’s High --
Today’s Low --
52 Week High 20.85
52 Week Low 9.51
Shares Outstanding (mil) 67.71
Market Capitalization (mil) 863.35
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.27 Mean rating from 15 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
2
FY16
0
EPS (USD)
FY19
-1.632
FY18
-4.877
FY17
-5.195
FY16
-3.222
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
1,264.05
7.92
Price to Book (MRQ)
vs sector
2.93
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
0.00
14.56
LT Debt to Equity (MRQ)
vs sector
0.00
10.21
Return on Investment (TTM)
vs sector
-76.39
14.49
Return on Equity (TTM)
vs sector
-76.45
15.79

EXECUTIVE LEADERSHIP

Robert Azelby
President, Chief Executive Officer, Director, Since 2018
Salary: $330,000.00
Bonus: --
Carlos Campoy
Chief Financial Officer, Since 2018
Salary: $22,077.00
Bonus: --
Erin Lavelle
Chief Operating Officer, Since 2018
Salary: $283,590.00
Bonus: --
James Bucher
Executive Vice President, General Counsel, Since 2019
Salary: $397,708.00
Bonus: --
Randal Hassler
Executive Vice President, Pharmaceutical Operations, Since 2018
Salary: $560,750.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11804 N Creek Pkwy S
BOTHELL   WA   98011-8801

Phone: +1425.2052900

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

SPONSORED STORIES